



UNITED STATES PATENT AND TRADEMARK OFFICE

CL

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/642,068	08/18/2000	John R. Stuepnagel	067234-0110	6751
7590	05/10/2005		EXAMINER	
David A. Gay MCDERMOTT WILL & EMERY LLP 4370 LaJolla Village Drive Suite 700 San Diego, CA 92122			STRZELECKA, TERESA E	
			ART UNIT	PAPER NUMBER
			1637	

DATE MAILED: 05/10/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief	Application No.	Applicant(s)
	09/642,068	STUELPNAGEL ET AL.
Examiner	Art Unit	
	Teresa E. Strzelecka	1637
--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --		
THE REPLY FILED <u>22 April 2005</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.		
<p>1. <input type="checkbox"/> The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:</p> <p>a) <input checked="" type="checkbox"/> The period for reply expires <u>6</u> months from the mailing date of the final rejection.</p> <p>b) <input type="checkbox"/> The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than <u>SIX MONTHS</u> from the mailing date of the final rejection.</p> <p>Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).</p>		
<p>Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).</p>		
NOTICE OF APPEAL		
<p>2. <input type="checkbox"/> The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).</p>		
AMENDMENTS		
<p>3. <input type="checkbox"/> The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because</p> <p>(a) <input type="checkbox"/> They raise new issues that would require further consideration and/or search (see NOTE below);</p> <p>(b) <input type="checkbox"/> They raise the issue of new matter (see NOTE below);</p> <p>(c) <input type="checkbox"/> They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or</p> <p>(d) <input type="checkbox"/> They present additional claims without canceling a corresponding number of finally rejected claims.</p>		
<p>NOTE: _____. (See 37 CFR 1.116 and 41.33(a)).</p>		
<p>4. <input checked="" type="checkbox"/> The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).</p>		
<p>5. <input type="checkbox"/> Applicant's reply has overcome the following rejection(s): _____. </p>		
<p>6. <input type="checkbox"/> Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).</p>		
<p>7. <input type="checkbox"/> For purposes of appeal, the proposed amendment(s): a) <input type="checkbox"/> will not be entered, or b) <input type="checkbox"/> will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.</p>		
<p>The status of the claim(s) is (or will be) as follows:</p>		
<p>Claim(s) allowed: _____.</p>		
<p>Claim(s) objected to: _____.</p>		
<p>Claim(s) rejected: _____.</p>		
<p>Claim(s) withdrawn from consideration: _____.</p>		
AFFIDAVIT OR OTHER EVIDENCE		
<p>8. <input type="checkbox"/> The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will <u>not</u> be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).</p>		
<p>9. <input type="checkbox"/> The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).</p>		
<p>10. <input type="checkbox"/> The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.</p>		
REQUEST FOR RECONSIDERATION/OTHER		
<p>11. <input checked="" type="checkbox"/> The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.</p>		
<p>12. <input type="checkbox"/> Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). <i>✓</i></p>		
<p>13. <input type="checkbox"/> Other: _____.</p>		
<p><i>TS 5/5/05</i></p>		
<p><i>JEFFREY FREDMAN PRIMARY EXAMINER 5/6/05</i></p>		

Continuation of 11. does NOT place the application in condition for allowance because:

A) Regarding teaching a pool of oligonucleotides, Applicants argue that a passage cited by Applicants from Holmes reference, col. 6, lines 36 and 37, does not teach or suggest generating pools of different oligonucleotides, and cite examiner's response. This passage was cited by Applicants in their response filed June 25, 2004 on page 11: "In this regard, the mere assertion at column 6, lines 36-37 that compounds synthesized on beads provided on a surface may be released upon completion of a synthesis does not teach or suggest generating a pool of different oligonucleotides because the compounds would have likely been released individually." The response of the examiner was that since Holmes does not specifically teach releasing the oligonucleotides individually, Applicants assertion that they would have been likely released individually is not based on the teachings of the reference. Further, Applicants chose to take only one of the cited passages which were supporting of cleaving oligonucleotides from beads, and omitted passages which were cited in support of teaching of different oligonucleotides, i.e. col. 2, lines 1-7 and column 10, lines 15-25. These paragraphs specifically teach diverse oligonucleotide sequences synthesized for use in high-density arrays. These passages were cited in paragraph 6A(a) of the rejection. Therefore, Applicants assertion that Holmes does not teach diverse oligonucleotides is not supported by facts. Applicants further state: "Regardless of certain descriptions in Holmes appearing to describe diverse populations of polymers, there is no showing of record or rationale described in Holmes for releasing a mixture of oligonucleotides from an array precisely assembled to have oligomers displayed at specific locations just to thereafter combine them into a pool of mixed oligonucleotide species." In response examiner contends that the rationale for performing a step is not taken into account when comparing the prior art with a claimed invention. As long as the steps disclosed by prior art are the same as steps claimed, the reference anticipates the steps.

B) Regarding teaching away, Applicants argue that the combination of references is improper because Beattie teaches away from Holmes. However, as indicated by MPEP 2123, non-preferred embodiments still constitute prior art:

"Rejection Over Prior Art's Broad Disclosure Instead of Preferred Embodiments

PATENTS ARE RELEVANT AS PRIOR ART FOR ALL THEY CONTAIN

"The use of patents as references is not limited to what the patentees describe as their own inventions or to the problems with which they are concerned. They are part of the literature of the art, relevant for all they contain." In re Heck, 699 F.2d 1331, 1332-33, 216 USPQ 1038, 1039 (Fed. Cir. 1983) (quoting In re Lemelson, 397 F.2d 1006, 1009, 158 USPQ 275, 277 (CCPA 1968)).

A reference may be relied upon for all that it would have reasonably suggested to one having ordinary skill the art, including nonpreferred embodiments. Merck & Co. v. Biocraft Laboratories, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989). See also Celeritas Technologies Ltd. v. Rockwell International Corp., 150 F.3d 1354, 1361, 47 USPQ2d 1516, 1522-23 (Fed. Cir. 1998) (The court held that the prior art anticipated the claims even though it taught away from the claimed invention. "The fact that a modem with a single carrier data signal is shown to be less than optimal does not vitiate the fact that it is disclosed.").

NONPREFERRED EMBODIMENTS CONSTITUTE PRIOR ART

Disclosed examples and preferred embodiments do not constitute a teaching away from a broader disclosure or nonpreferred embodiments. In re Susi, 440 F.2d 442, 169 USPQ 423 (CCPA 1971). "A known or obvious composition does not become patentable simply because it has been described as somewhat inferior to some other product for the same use." In re Gurley, 27 F.3d 551, 554, 31 USPQ2d 1130, 1132 (Fed. Cir. 1994) (The invention was directed to an epoxy impregnated fiber-reinforced printed circuit material. The applied prior art reference taught a printed circuit material similar to that of the claims but impregnated with polyester-imide resin instead of epoxy. The reference, however, disclosed that epoxy was known for this use, but that epoxy impregnated circuit boards have "relatively acceptable dimensional stability" and "some degree of flexibility," but are inferior to circuit boards impregnated with polyester-imide resins. The court upheld the rejection concluding that applicant's argument that the reference teaches away from using epoxy was insufficient to overcome the rejection since "Gurley asserted no discovery beyond what was known in the art." 27 F.3d at 554, 31 USPQ2d at 1132.)"

Further, Applicants arguments of teaching away are based on the implicit assumption that the at least first and second oligonucleotides are released simultaneously from the support, resulting in a mixture of first and second oligonucleotides, which is not a limitation present in the claims, since the claims teach releasing pools of first and second oligonucleotides, and both Holmes and Beattie teach just that. Further, since Holmes teaches high density arrays, where oligonucleotides of known sequence are attached to predetermined locations, Holmes inherently teaches releasing the different types of oligonucleotides separately, which is exactly what Beattie does. Therefore, since Holmes teaches releasing diverse oligonucleotides from support for the purpose of making high-density arrays and using them in biological assays, and since Beattie teaches releasing diverse oligonucleotides from support to make high-density arrays and contacting the oligonucleotides on the arrays with target nucleic acids for the purpose of detecting target nucleic acids by hybridization, these two references can be combined with high expectation of success, and Beattie does not teach away from Holmes.

C) Regarding the motivation to combine the references, Applicants argue that an array of oligonucleotides of Beattie produced by the method of Holmes would not be operational for the purposes disclosed by Beattie. However, as stated above, Applicants implicitly assume that the claims are drawn to releasing the first and second pools simultaneously, and this issue was addressed above.

Therefore, Applicants arguments are not considered to be persuasive in overcoming the rejections of claims over the combination of Holmes and Beattie.

Notice of Non-Compliant Amendment (37 CFR 1.121)	Application No.	Applicant(s)
	09/642,068	STUELPNAGEL ET AL.
	Examiner Teresa E. Strzelecka	Art Unit 1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

The amendment document filed on 22 April 2005 is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121. In order for the amendment document to be compliant, correction of the following item(s) is required.

THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AMENDMENT DOCUMENT TO BE NON-COMPLIANT:

- 1. Amendments to the specification:
 - A. Amended paragraph(s) do not include markings.
 - B. New paragraph(s) should not be underlined.
 - C. Other _____.
- 2. Abstract:
 - A. Not presented on a separate sheet. 37 CFR 1.72.
 - B. Other _____.
- 3. Amendments to the drawings:
 - A. The drawings are not properly identified in the top margin as "Replacement Sheet," "New Sheet," or "Annotated Sheet" as required by 37 CFR 1.121(d).
 - B. The practice of submitting proposed drawing correction has been eliminated. Replacement drawings showing amended figures, without markings, in compliance with 37 CFR 1.84 are required.
 - C. Other _____.
- 4. Amendments to the claims:
 - A. A complete listing of all of the claims is not present.
 - B. The listing of claims does not include the text of all pending claims (including withdrawn claims)
 - C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. Note: the status of every claim must be indicated after its claim number by using one of the following status identifiers: (Original), (Currently amended), (Canceled), (Previously presented), (New), (Not entered), (Withdrawn) and (Withdrawn-currently amended).
 - D. The claims of this amendment paper have not been presented in ascending numerical order.
 - E. Other: _____.

For further explanation of the amendment format required by 37 CFR 1.121, see MPEP § 714 and the USPTO website at <http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/officeflyer.pdf>.

TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:

1. Applicant is given **no new time period** if the non-compliant amendment is an after-final amendment or an amendment filed after allowance. If applicant wishes to resubmit the non-compliant after-final amendment with corrections, the **entire corrected amendment** must be resubmitted within the time period set forth in the final Office action.
2. Applicant is given **one month**, or thirty (30) days, whichever is longer, from the mail date of this notice to supply the **corrected section** of the non-compliant amendment in compliance with 37 CFR 1.121, if the non-compliant amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension period under 37 CFR 1.103(a) or (c), and an amendment filed in response to a *Quayle* action.

Extensions of time are available under 37 CFR 1.136(a) **only** if the non-compliant amendment is a non-final amendment or an amendment filed in response to a *Quayle* action.

Failure to timely respond to this notice will result in:

Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendment filed in response to a *Quayle* action; or

Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental amendment.